Quercetin has been used with other nutraceutical components to improve renal function. Its potential to be developed as an active pharmaceutical ingredient, however, is limited by poor aqueous solubility and low rate of dissolution leading to low bioavailability in rats (< 17%) and in human (1%). Solid dispersion of quercetin with PVP K30 has increased its solubility 13.24 times and the amount dissolved (95.12 ± 1.83%) in comparison to pure quercetin. This study aimed to determine the nephron-protection effect of the solid dispersion on Acute Renal Failure (ARF) mice. The animals were divided into 6 groups, normal mice as a negative control group (G1), ARF induced mice as a positive control group (G2), ARF induced mice given pure quercetin 50 mg/kg BW (G3), ARF induced mice given solid dispersion containing 10 mg/ kg BW (G4), 5 mg/kg BW (G5) and 2.5 mg/kg BW (G6) quercetin respectively. The ARF was induced by injection of gentamycin sulphate 100 mg/kg BW for 7 days consecutively. Renal function was monitored by measuring the serum creatinine at day 8 th. The protection effect was also observed from the histopathology score of the nephrons. Results showed that ARF induction increased serum creatinine above normal. Solid dispersion doses variations significantly influence the serum creatinine (p < 0.05). The stage of renal impairment based on histopathology score was significantly influenced by the doses of quercetin in solid dispersion (p < 0.05). It was concluded that solid dispersion containing quercetin at doses 2.5 and 5.0 mg/ kg BW respectively did not effective as a nephron-protector. The solid dispersion containing quercetin 10.0 mg/kg BW was effective to reduce the serum creatinine and showed a nephronprotection effect on the ARF induced mice.